Breast Cancer Vaccine Kills Tumors in Mice
Posted on: Monday, 15 September 2008, 18:00 CDT
Wayne State University researchers say a breast cancer vaccine completely eliminated HER2-positive tumors in mice -- without any toxicity.
The study, published in the journal Cancer Research, suggests the vaccine could treat women with HER2-positive, treatment-resistant cancer or help prevent cancer recurrence. The researchers also say it might potentially be used in cancer-free women to prevent initial development of these tumors.
HER2 receptors promote normal cell growth, and are found in low amounts on normal breast cells. But HER2-positive breast cells can contain many more receptors than is typical, promoting a particularly aggressive type of tumor that affects 20 percent to 30 percent of all breast cancer patients, the study says.
Therapies such as trastuzumab and lapatinib, designed to latch on to these receptors and destroy them, are a mainstay of treatment for this cancer, but a significant proportion of patients develop a resistance to them or cancer metastasis that is hard to treat.
"The immune response against HER2-positive receptors we saw in this study is powerful, and works even in tumors that are resistant to current therapies," lead investigator Wei-Zen Wei says in a statement.
"The vaccine could potentially eliminate the need to even use these therapies."
Source: United Press International
Related Articles
- Study Finds It's Safe To Treat HER2-Positive Breast Cancer With Trastuzumab And Adjuvant Radiation
- Early-Stage, HER2-Positive Breast Cancer Patients At Increased Risk Of Recurrence
- If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
- ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Patients With Metastatic, HER2-Positive Breast Cancer
- Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
- GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
- Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
- Fourth Phase III Study Shows Herceptin(R) Plus Chemotherapy Improved Disease- Free Survival in Early-Stage HER2-Positive Breast Cancer
- Herceptin Plus Chemotherapy Improved Disease-Free Survival and Overall Survival in Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
- Interim Analysis of Phase III Studies Shows Herceptin Plus Chemotherapy Improves Disease-Free Survival in the Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
 |
 |
User Comments (0)
RSS Feeds